Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency

Journal of Infectious Diseases

Volumn 173, Issue 2, 1996, Pages 291-299

  Thackray, Alana M ^a   Field, Hugh J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FAMCICLOVIR; VALACICLOVIR;

ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; FEMALE; HERPES SIMPLEX VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL GANGLION; TRIGEMINUS GANGLION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0030034396     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.2.291     Document Type: Article

References (29)

1. Wildy P, Field HJ, Nash AA. Classical herpes latency revisited. In: Virus persistence (symposium 33, Society for General Microbiology). Cambridge, UK: Cambridge University Press, 1982:133-67.
2. Fraser N, Valyi-Nagy T. Viral, neuronal, and immune factors which may influence herpes simplex virus (HSV) latency and reactivation. Microb Pathog 1993;15:83-91.
3. Kristensson K. Retrograde transport of macromolecules in axons. Annu Rev Pharmacol Toxicol 1978;18:97-110.
4. Field HJ, Bell SE, Elion GB, Nash AA, Wildy P. Effect of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother 1979;15:554-61.
5. Hill TJ, Field HJ, Blyth WA. Acute and recurrent infection with herpes simplex in the mouse: a model for studying latency and recurrent disease. J Gen Virol 1975;28:341-53.
6. Klein RJ, Friedman-Kien AE, DeStefano E. Latent herpes simplex infections in sensory ganglia of hairless mice prevented by acycloguanosine. Antimicrob Agents Chemother 1979;15:723-9.
7. Klein RJ, Friedman-Kien AE, DeStefano E. Effect of discontinuous acyclovir treatment on in vitro reactivation of herpes simplex virus from latently infected trigeminal ganglia. Antimicrob Agents Chemother 1983;24:129-31.
8. Klein RJ, Friedman-Kien AE. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on the acute local phase of herpes simplex virus-induced skin infections in mice and the establishment of latency. Antimicrob Agents Chemother 1985;27:763-8.
9. Field HJ, De Clercq E. Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment and maintenance of latent herpes simplex virus infection in mice. J Gen Virol 1981;56:259-65.
10. Blyth WA, Harbour DA, Hill TJ. Effect of acyclovir on recurrence of herpes simplex lesions in mice. J Gen Virol 1980;48:417-9.
11. Nesburn AB, Willey DE, Trousdale MD. Effect of intensive acyclovir therapy during artificial reactivation of latent herpes simplex virus. Proc Soc Exp Biol Med 1983;172:316-23.
12. Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent (BRL 39123) [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrob Agents Chemother 1989;33:1765-73.
13. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother 1993;4:47-55.
14. Beauchamp LM, Orr GF, de Miranda P, Burnette T, Schaeffer HJ, Krenitsky TA. Amino acid ester prodrugs of acyclovir. Antiviral Chem Chemother 1992;3:157-64.
15. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
16. Field HJ, Tewari D, Sutton D, Thackray AM. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrob Agents Chemother 1995;39:1114-9.
17. Field HJ, Thackray AM. The effects of delayed-onset chemotherapy using famciclovir or valaciclovir in a murine immunosuppression model for HSV-1. Antiviral Chem Chemother 1995;6:210-6.
18. Boyd MR, Bacon TH, Sutton D. Antiherpes activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in animals. Antimicrob Agents Chemother 1988;32:358-63.
19. Sutton D, Boyd MR. Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. Antimicrob Agents Chemother 1993;37:642-5.
20. Harnden MR, Jarvest RL, Boyd MR, Sutton D, Vere Hodge RA. Prodrugs of the selective antiviral agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties. J Med Chem 1989;32:1738-43.
21. Goldthorpe SE, Boyd MR, Field HJ. Effects of penciclovir and famciclovir in a murine model of encephalitis induced by intranasal inoculation of herpes simplex type 1. Antiviral Chem Chemother 1992;3:37-47.
22. Sutton D, Taylor J, Bacon TH, Boyd MR. Activity of penciclovir in combination with azidothymidine, ganciclovir, acyclovir, foscarnet, and human interferons against herpes simplex virus replication in cell culture. Antiviral Chem Chemother 1992;3:85-94.
23. Thackray AM, Field HJ. Comparative effects of famciclovir and valaciclovir on cutaneous and neurological HSV-1 infection in normal and immunocompromised mice. Antiviral Res 1995;26:A328.
24. Vere Hodge RA, Cheng YC. The mode of action of penciclovir. Antiviral Chem Chemother 1993;4:13-24.
25. Field HJ, Goldthorpe SE. Antiviral drug resistance. Trends Pharmacol Sci 1989;10:333-7.
26. Jacobson J, Kramer M, Rozenberg F, Hu A, Coen DM. Synergistic effects on ganglionic herpes simplex virus infections by mutations or drugs that inhibit the viral polymerase and thymidine kinase. Virology 1995;206:263-8.
27. Ecob-Prince MS, Hassan K, Denheen MT, Preston CM. Expression of β-galactosidase in neurons of dorsal root ganglia which are latently infected with herpes simplex virus type 1. J Gen Virol 1995;76: 1527-32.
28. Mehta A, Maggioncalda J, Bagasra O, et al. In situ DNA PCR and RNA hybridization detection of herpes simplex virus sequences in trigeminal ganglia of latently infected mice. Virology 1995;206:633-40.
29. Ramakrishnan R, Levine M, Fink DJ. PCR-based analysis of herpes simplex virus type 1 latency in the rat trigeminal ganglion established with a ribonucleotide reductase-deficient mutant. J Virol 1994;68:7083-91.